ChengDu ShengNuo Biotec Co.,Ltd.

Shanghai Stock Exchange 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 123.94 M

ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity is USD 123.94 M for the year ending December 31, 2023, a 3.45% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 119.80 M, a -3.04% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 123.56 M, a 84.33% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 67.04 M, a 24.00% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 54.06 M, a 13.58% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shanghai Stock Exchange: 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd.

CEO	Mr. Yongjun Wen
IPO Date	June 3, 2021
Location	China
Headquarters	258 Industrial Avenue Section
Employees	1,128
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Key trends

Past 5 years